Combined PET Imaging and Diffusion-Weighted Imaging of Intermediate and High-Risk Primary Prostate Carcinomas with Simultaneous [18F] Choline PET/MRI
暂无分享,去创建一个
A. Wetter | M. Forsting | P. Heusch | F. Nensa | A. Bockisch | T. Schlosser | T. Lauenstein | J. Nagarajah | T. Pöppel | M. Schenck
[1] G. Tomasi,et al. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer , 2014, Nuclear medicine communications.
[2] Eisaku Ito,et al. Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer , 2014, International Urology and Nephrology.
[3] Zhaoqin Huang,et al. Diffusion-weighted imaging of prostate cancer on 3T MR: Relationship between apparent diffusion coefficient values and Ki-67 expression. , 2013, Academic radiology.
[4] M. Haider,et al. The expanding role of MRI in prostate cancer. , 2013, AJR. American journal of roentgenology.
[5] C. Geppert,et al. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI. , 2013, AJR. American journal of roentgenology.
[6] P. V. van Diest,et al. Why prostate tumour delineation based on apparent diffusion coefficient is challenging: An exploration of the tissue microanatomy , 2013, Acta oncologica.
[7] K. Sugimura,et al. Do apparent diffusion coefficient (ADC) values obtained using high b-values with a 3-T MRI correlate better than a transrectal ultrasound (TRUS)-guided biopsy with true Gleason scores obtained from radical prostatectomy specimens for patients with prostate cancer? , 2013, European journal of radiology.
[8] Sibylle Ziegler,et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[9] Felix Nensa,et al. Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate: Initial Results , 2013, Investigative radiology.
[10] Thomas Hambrock,et al. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. , 2013, Radiology.
[11] Karl-Olof Lovblad,et al. Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[12] M. Schwaiger,et al. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model]. , 2013, Nuklearmedizin. Nuclear medicine.
[13] T. Schuster,et al. Ansprechen auf eine Docetaxel-therapie im LNCaP-Prostata-karzinom-Xenograft-Mausmodell , 2013, Nuklearmedizin.
[14] M. Schwaiger,et al. [11C]choline as a pharmacodynamic marker for docetaxel therapy , 2013 .
[15] James Nagarajah,et al. Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[16] J. Bussink,et al. Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation , 2013, European Radiology.
[17] Jian-Rong Xu,et al. Usefulness of diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer. , 2012, Academic radiology.
[18] L. Bains,et al. Therapy response with diffusion MRI: an update , 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.
[19] M. Nomoto,et al. FDG PET/CT and Diffusion-Weighted Imaging of Head and Neck Squamous Cell Carcinoma: Comparison of Prognostic Significance Between Primary Tumor Standardized Uptake Value and Apparent Diffusion Coefficient , 2012, Clinical nuclear medicine.
[20] G. Bauman,et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature , 2011, Prostate Cancer and Prostatic Diseases.
[21] Celia P. Corona-Villalobos,et al. Oncologic applications of diffusion‐weighted MRI in the body , 2012, Journal of magnetic resonance imaging : JMRI.
[22] H. Thoeny,et al. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. , 2012, European urology.
[23] Z. Bhujwalla,et al. Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.
[24] S. Hazell,et al. Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression , 2011, Clinical Cancer Research.
[25] K. Chang,et al. Correlation of 18F-FDG Uptake with Apparent Diffusion Coefficient Ratio Measured on Standard and High b Value Diffusion MRI in Head and Neck Cancer , 2011, The Journal of Nuclear Medicine.
[26] Manish Kakar,et al. Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study , 2011, Radiation oncology.
[27] F. Mottaghy,et al. Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT. , 2010, Clinical nuclear medicine.
[28] A. Jemal,et al. Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[29] Brian D Ross,et al. Predicting and monitoring cancer treatment response with diffusion‐weighted MRI , 2010, Journal of magnetic resonance imaging : JMRI.
[30] C. Kim,et al. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. , 2010, AJR. American journal of roentgenology.
[31] P. Waldenberger,et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.
[32] Nassir Navab,et al. Tissue Classification as a Potential Approach for Attenuation Correction in Whole-Body PET/MRI: Evaluation with PET/CT Data , 2009, Journal of Nuclear Medicine.
[33] R. Tiling,et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[34] R. Rosell,et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.
[35] S B Malkowicz,et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. , 2001, The Journal of urology.